DWQA Questions › Tag: pharmaceutical approach
Filter:AllOpenResolvedClosedUnanswered
In 2001, the National Institutes of Health (NIH) launched a trial to lower blood glucose levels in diabetic patients to reduce their risk for heart attack, stroke, or death from cardiovascular disease. The trial, called Action to Control Cardiovascular Risk in Diabetes, or ACCORD, involved over 10,000 Type 2 diabetic patients who had either been previously diagnosed with heart disease or had two or more risk factors for heart disease when they entered the study. Half received standard treatment and half were treated aggressively with higher doses of antidiabetic drugs. The trial was halted 18 months early because of a 26% increase in deaths in the aggressively treated group. The NIH said there was no conclusive link to a particular medication. Were these outcomes just a fluke or was over-medication involved? What is Creator’s perspective?
ClosedNicola asked 2 days ago • 
10 views0 answers0 votes
The diabetes drug rosiglitazone, sold under the trade name Avandia, has come under scrutiny. From 1999 to 2009, nearly 50,000 people on Avandia suffered heart attack, stroke, heart failure or death. In Europe, the European Medicines Agency (EMA) recommended in September 2010 that the drug be suspended because the benefits no longer outweighed the risks.[10][11] It was withdrawn from the market in the UK, Spain and India in 2010,[12] and in New Zealand and South Africa in 2011. It is still being prescribed in the U.S. following a review of safety data by the FDA. Is this drug safe to use or are there cardiovascular risks? What is Creator’s perspective?
ClosedNicola asked 2 days ago • 
7 views0 answers0 votes
Ask Question